Compugen has dosed the first patient in a proof-of-concept clinical trial of triple immunotherapy combination of COM701, COM902 and pembrolizumab to treat platinum-resistant ovarian cancer.

The open-label study is initiated based on the encouraging data of the Phase I cohort expansion trial evaluating the combination of COM701 and nivolumab ± BMS-986207 in platinum resistant ovarian cancer patients.

In this trial, the triple immunotherapy combination of COM701, COM902 and pembrolizumab will be evaluated in nearly 40 patients with high-grade platinum resistant epithelial ovarian cancer.

Patients with primary peritoneal and fallopian tube cancer who previously received up to three lines of therapies, and all histologies are included in the study.

Compugen president and CEO Anat Cohen-Dayag said: “We expect that this study will help us to better understand the contribution of the components and contribute to our ongoing biomarker work to try and identify the patients most likely to respond, with the purpose of building a path to registration.”

Initial findings from the trial are anticipated by the end of this year.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

COM701 is an anti-PVRIG antibody while COM902 antibody targets TIGIT. Both are used for treating solid tumours.

A PD-1/TIGIT bi-specific, rilvegostomig derived from COM902 is in Phase II development by AstraZeneca under a licence agreement.

Compugen’s pipeline of therapeutic includes early-stage immuno-oncology programmes with the most advanced being COM503.

COM503 blocks the interaction between IL-18 binding protein and frees natural IL-18 for inhibiting cancer growth in the tumour microenvironment. It is in IND enabling studies.